Close menu




October 29th, 2020 | 13:19 CET

SAP, Triumph Gold, JinkoSolar - Mutti blows to get started!

  • Investments
Photo credits: pixabay.com

It seems done. Yesterday afternoon, the German Chancellor Angela Merkel (German nickname: Mutti) decided on the second lockdown of this year due to the vastly increasing number of cases in the Corona Pandemic. Although this lockdown is supposed to be somewhat "lighter and more social" than the first, it is causing uncertainty among the population and the capital markets. It remains to be seen whether the stock markets will reach a new low after the experience in spring, or whether they will only get shaken vigorously for a short time. Should the worst-case scenario occur, the central banks with their money printing machines will undoubtedly be ready again. So a second chance to get started? In any case, keep an eye on gold stocks.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA8968121043 , DE0007164600 , US47759T1007

Table of contents:


    Chance from the second row

    After the gold price reached its high of over USD 2,030.00 in early August, it has since corrected at a high level of around USD 1,900.00. Uncertainties due to the pandemic, the US elections - which will be finalized on November 3, and the high national debt, should provide the precious metal with a further tailwind. Triumph Gold, a growth-oriented Canadian gold exploration and development Company with a large land package in the mining-friendly Yukon, has also returned to lower price level. While the value in the summer of 2019 was still at CAD 0.72, the current value is only CAD 0.22. The market capitalization is the equivalent of almost EUR 20 million.

    Program expansion

    Recently, the Canadians announced that it had completed the fully funded exploration program PR20-07. This program included minor trenching and reconnaissance sampling as well as 2,068 metres of diamond drilling. The partially near-surface surveys are now in the evaluation and analysis phase. According to Jesse Halle, Vice President of Exploration, several of the reconnaissance samples collected indicate that gold mineralization is much more widespread than previously thought. As a result, the 2021 exploration program will expand.

    Conflicting quarterly figures!

    SAP would have expected the third quarter figures to sound similar to those of its competitor, Microsoft. After all, it was precisely the cloud business that helped the US Americans to achieve a leap in profits because of the Corona pandemic. In the past financial quarter, which lasted until the end of September, profits increased by 30 percent year-on-year to USD 13.9 billion. Revenue grew by twelve percent to USD 37.2 billion. "Demand for our cloud offerings led to a strong start to the financial year," said Amy Hood, CFO of Microsoft.

    Disappointment all along the line

    Microsoft's joker, the Cloud business, was responsible for the weak results of the Walldorf-based Company, which felt the full force of the crisis at SAP. The plan for the Cloud Division was for sales of EUR 8.3 to 8.7 billion, but now the figure is still EUR 8 to 8.2 billion.

    Analysts lower targets

    The development of the former model Company was also incomprehensible to the analysts. Goldman Sachs, for example, took the Walldorf-based Company off the "Conviction Buy List" and lowered its price target from EUR 160 to the current EUR 120. JP Morgan kept the value at "neutral" and left the price target at 120 EUR. The attempt by Hasso Plattner, former CEO and current Supervisory Board member, to support the share price at around EUR 100 by purchasing SAP shares with a value of EUR 250 million failed, for the time being. The share is currently still in free fall at just under EUR 94.

    Still promising

    One of the world's leading companies in the photovoltaic industry, JinkoSolar, was forced to give up feathers despite a buy recommendation from the leading Swiss bank. The target price was raised to USD 55. However, this means that the current share price of 57 USD is still above the target price. The quarterly figures announced for today should be exciting. In any case, there is no way around investing in solar stocks in the future.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 30th, 2022 | 10:59 CEST

    Biogen, XPhyto, BioNTech: Alzheimer's disease, depression, cancer - Pharma for life

    • Biotechnology
    • Pharma
    • Investments
    • Technology

    About 350 million people worldwide are affected by depression, a disorder of the brain. Each person also has a 16 to 20% chance of becoming depressed. Reason enough for the Canadian Company XPhyto Therapeutics to research a drug that is not addictive and can defeat the mental health-related medical condition. This week, Biogen, among others, achieved a breakthrough with an active substance against Alzheimer's disease. And if you follow the Bundesliga closely, you may be aware of the cases of testicular cancer among the players. Now BioNTech senses a new opportunity...

    Read

    Commented by Fabian Lorenz on September 29th, 2022 | 13:17 CEST

    Up to 200% share price potential: Kion, BioNTech, Aspermont in analyst check

    • Technology
    • Biotechnology
    • Investments

    The profit warning was a shock for Kion shareholders. Accordingly, the share price halved to EUR 20 in September alone. Now analysts are also slashing their estimates. The price targets for the forklift manufacturer are falling accordingly. Berenberg surprises with a high price target for the BioNTech share. At the same time, the analysts emphasize their hope for a continued generous dividend. Shareholders could thus be kept in good spirits until the next blockbuster. The roadshow of Aspermont in Germany has probably also created a good mood. At least the share price has jumped. The current consolidation could be an entry opportunity. Analysts see a price potential of over 200%.

    Read

    Commented by Carsten Mainitz on September 29th, 2022 | 12:01 CEST

    Verbio, Kleos Space, KWS Saat - This news is moving share prices!

    • Space
    • Technology
    • Investments

    Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

    Read